Half Year Results voestalpine AG: voestalpine holds its own in the first half of 2024/25 in an overall challenging economic environment 13.11.2024 / 07:30 CET/CEST The issuer is solely responsible for ...
AI-fluent CMOs are becoming a transformative force in business; 62% see their influence growing over broader corporate decisions as their AI implementations look to improve ...
Strategic Company Decision AGRANA NEXT LEVEL: Supervisory Board approves new group strategy 12.11.2024 / 12:50 CET/CEST The issuer is solely responsible for the content of this announcement.
Month figures wienerberger: Solid Q3 Results Highlight Resilience and Sustainable Growth 12.11.2024 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement.
Personnel Kapsch TrafficCom appoints Phil Thompson as North America Vice President of Sales and Business Development 12.11.2024 / 14:00 CET/CEST The issuer is solely responsible for the content of ...
Personnel Mayr-Melnhof Karton AG: MM Group expands Management Board (news with additional features) 11.11.2024 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement.
Quarter Results/9 Month figures VERBUND AG: Results for quarters 1–3/2024: Decline in earnings despite good water supply and higher wind and PV output 07.11.2024 / 07:59 CET/CEST The issuer is solely ...
Quarter Results Mayr-Melnhof Karton AG: MM reports results for the first three quarters of 2024 07.11.2024 / 08:00 CET/CEST The issuer is solely responsible for the content of this announcement.
Quarter Results Semperit increases profitability in Q1–3 and confirms outlook for 2024 07.11.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement.
Month figures/Quarter Results ANDRITZ reports solid development in Q3 2024 31.10.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement.
PRESS INFORMATION COVID-19 vaccination for diabetics: antibody level comparable to healthy individuals When the first vaccines against COVID-19 became available, there was great uncertainty – ...
The Phase III trial AV001 aims to evaluate QUTENZA® in post- surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after ...